Open AccessSolasodine inhibits human colorectal cancer cells through suppression of the AKT /glycogen synthase kinase‐3β/β‐catenin pathway
Author(s) -
Zhuang Yuwen,
Wu Cunen,
Zhou Jinyong,
Chen Xu,
Wu Jian,
Jiang Shan,
Peng Haiyan,
Zou Xi,
Liu Jiayun,
Wu Dapeng,
Gong Tao,
Qi Minghao,
Xue Tian,
Liu Shenlin,
Cai Hui
Publication year - 2017
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13354
Subject(s) - solasodine , cancer research , protein kinase b , glycogen synthase , gsk 3 , cell growth , apoptosis , biology , chemistry , pharmacology , microbiology and biotechnology , endocrinology , kinase , insulin , biochemistry , botany , solanum
Solasodine is a main active component isolated from Solanum incanum L. that performs a wide range of functions containing anti‐oxidant, anti‐infection, and neurogenesis promotion. In this study, we explored the influence of solasodine on three types of human colorectal cancer ( CRC ) cell lines. The results show that solasodine prohibited CRC cell proliferation dose‐ and time‐dependently and impeded CRC cell motility by downregulating MMP s. Solasodine was also found to fuel caspase‐cascade reaction and increase the ratio between Bax and Bcl‐2 so as to induce CRC cell apoptosis. When cells were pretreated with AKT activator (insulin‐like growth factor‐1) followed by solasodine, the solasodine‐induced apoptosis was partially abrogated by insulin‐like growth factor‐1. Moreover, solasodine hindered tumor development and stimulated similar mechanisms in vivo . In general, our study provides the first evidence that solasodine has a suppressive effect on CRC cells and that this agent may be a novel therapeutic drug for CRC treatment.